Peer-influenced content. Sources you trust. No registration required. This is HCN.


Journal of Clinical Oncology

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update

Oncology, Medical April 26th 2022

Clinical Advances in Hematology & Oncology

Highlights in Metastatic Breast Cancer From the 2021 San Antonio Breast Cancer Symposium (SABCS)

Oncology, Medical February 15th 2022

Journal of Clinical Oncology

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy with or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Oncology, Medical February 1st 2022

FDA Grants Fast Track Status to Cosela for Triple-Negative Breast Cancer (TNBC)

Internal Medicine July 26th 2021

FDA Approves Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC

Hematology November 16th 2020

ASCO20: Maintenance Metronomic Capecitabine Extends DFS in TNBC

Hematology June 1st 2020